DK3390448T3 - Intravesikal terapi af blærekræft - Google Patents
Intravesikal terapi af blærekræft Download PDFInfo
- Publication number
- DK3390448T3 DK3390448T3 DK16819062.7T DK16819062T DK3390448T3 DK 3390448 T3 DK3390448 T3 DK 3390448T3 DK 16819062 T DK16819062 T DK 16819062T DK 3390448 T3 DK3390448 T3 DK 3390448T3
- Authority
- DK
- Denmark
- Prior art keywords
- bladder cancer
- intravesical therapy
- intravesical
- therapy
- bladder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1522311.8A GB201522311D0 (en) | 2015-12-17 | 2015-12-17 | Use |
| PCT/EP2016/081798 WO2017103280A1 (en) | 2015-12-17 | 2016-12-19 | Intravesical therapy for bladder cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3390448T3 true DK3390448T3 (da) | 2024-07-22 |
Family
ID=55311161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16819062.7T DK3390448T3 (da) | 2015-12-17 | 2016-12-19 | Intravesikal terapi af blærekræft |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20180371101A1 (https=) |
| EP (1) | EP3390448B1 (https=) |
| JP (1) | JP2018538308A (https=) |
| KR (1) | KR102878726B1 (https=) |
| CN (1) | CN108699147B (https=) |
| AU (1) | AU2016372570B2 (https=) |
| DK (1) | DK3390448T3 (https=) |
| ES (1) | ES2981986T3 (https=) |
| FI (1) | FI3390448T3 (https=) |
| GB (1) | GB201522311D0 (https=) |
| PL (1) | PL3390448T3 (https=) |
| WO (1) | WO2017103280A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| GB201522311D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| CN110300599B (zh) | 2016-12-07 | 2024-07-02 | 艾吉纳斯公司 | 抗体和其使用方法 |
| MY181242A (en) * | 2017-12-01 | 2020-12-21 | Sbi Pharmaceuticals Co Ltd | Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor |
| KR20250154511A (ko) | 2023-03-07 | 2025-10-28 | 포토큐어 에이에스에이 | 방광암 치료 |
| WO2026052815A1 (en) | 2024-09-05 | 2026-03-12 | Photocure Asa | Use of hal in a method for predicting bladder cancer immunotherapy response |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU225148B1 (en) | 1995-03-10 | 2006-07-28 | Photocure Asa | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy or diagnosis, products and kits comprising thereof and method of in vitro diagnosis by their using |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| GB0406917D0 (en) | 2004-03-26 | 2004-04-28 | Photocure Asa | Compounds |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| US8552154B2 (en) * | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| MX368257B (es) | 2011-08-01 | 2019-09-26 | Genentech Inc | Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer. |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2689760C2 (ru) | 2012-05-31 | 2019-05-30 | Дженентек, Инк. | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов |
| ES2994611T3 (en) * | 2015-10-19 | 2025-01-27 | Cg Oncology Inc | Methods of treating solid or lymphatic tumors by combination therapy |
| GB201522309D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| GB201522311D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
-
2015
- 2015-12-17 GB GBGB1522311.8A patent/GB201522311D0/en not_active Ceased
-
2016
- 2016-12-19 FI FIEP16819062.7T patent/FI3390448T3/fi active
- 2016-12-19 DK DK16819062.7T patent/DK3390448T3/da active
- 2016-12-19 CN CN201680079683.1A patent/CN108699147B/zh active Active
- 2016-12-19 PL PL16819062.7T patent/PL3390448T3/pl unknown
- 2016-12-19 ES ES16819062T patent/ES2981986T3/es active Active
- 2016-12-19 JP JP2018532038A patent/JP2018538308A/ja active Pending
- 2016-12-19 EP EP16819062.7A patent/EP3390448B1/en active Active
- 2016-12-19 AU AU2016372570A patent/AU2016372570B2/en active Active
- 2016-12-19 WO PCT/EP2016/081798 patent/WO2017103280A1/en not_active Ceased
- 2016-12-19 US US16/063,169 patent/US20180371101A1/en not_active Abandoned
- 2016-12-19 KR KR1020187020008A patent/KR102878726B1/ko active Active
-
2019
- 2019-04-18 US US16/388,379 patent/US11066478B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017103280A1 (en) | 2017-06-22 |
| WO2017103280A9 (en) | 2017-11-09 |
| US11066478B2 (en) | 2021-07-20 |
| KR20180094988A (ko) | 2018-08-24 |
| AU2016372570A1 (en) | 2018-07-12 |
| AU2016372570B2 (en) | 2024-01-18 |
| CA3008548A1 (en) | 2017-06-22 |
| US20180371101A1 (en) | 2018-12-27 |
| RU2018124866A (ru) | 2020-01-17 |
| EP3390448B1 (en) | 2024-06-05 |
| RU2018124866A3 (https=) | 2020-02-26 |
| EP3390448A1 (en) | 2018-10-24 |
| PL3390448T3 (pl) | 2024-09-16 |
| GB201522311D0 (en) | 2016-02-03 |
| FI3390448T3 (fi) | 2024-07-10 |
| BR112018012116A2 (en) | 2018-12-04 |
| JP2018538308A (ja) | 2018-12-27 |
| CN108699147A (zh) | 2018-10-23 |
| KR102878726B1 (ko) | 2025-10-29 |
| CN108699147B (zh) | 2022-11-01 |
| ES2981986T3 (es) | 2024-10-14 |
| US20190241672A1 (en) | 2019-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255261A0 (en) | Methods for treating cancer | |
| PL3283527T3 (pl) | Leczenie skojarzone nowotworów | |
| DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
| IL263802A (en) | Cancer treatment combinations | |
| DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
| HUE059694T2 (hu) | Készítmény rák kezelésére | |
| LT3277842T (lt) | Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais | |
| DK3262066T4 (da) | Genterapi | |
| IL258521B1 (en) | Combination therapy for the treatment of cancer | |
| PL3197456T3 (pl) | Leczenie nowotworów | |
| DK3622953T3 (da) | Kombinationsbehandling af cancer | |
| EP3413927A4 (en) | CANCER THERAPY | |
| LT3576740T (lt) | Vėžio gydymas | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| PT3134119T (pt) | Tratamento do cancro | |
| DK3390448T3 (da) | Intravesikal terapi af blærekræft | |
| DK3393478T3 (da) | Kombinationsterapi | |
| EP3362091A4 (en) | COMBINATION THERAPY | |
| DK3532076T3 (da) | Immunterapeutiske behandlinger af tumorer | |
| IL254825A0 (en) | Methods of treatment with taselisib | |
| DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin | |
| IL246558A0 (en) | Novel methods for treating cancer | |
| KR20180084983A (ko) | 암의 치료를 위한 피리미도-피리미다지논의 용도 | |
| LT3324951T (lt) | Peritoninis terapinis skystis | |
| DK3407909T3 (da) | Cancerbehandling |